Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
April 11, 2023
In this blog, we make the case that WHO should shift away from disease siloes and reorganize to streamline the cross-cutting functions that it delivers to member countries. The WHO has an opportunity to streamline its functions along the continuum of science practice—from registering clinical trials...
Blog Post
February 23, 2021
In 2020, epidemiological modelling went from relative obscurity to being central in helping governments, and the public, understand COVID-19 as it spread around the world. In 2021, with the emergence of effective COVID-19 vaccines, Health Technology Assessment (HTA) will be critical to making the be...
Blog Post
June 14, 2017
Here, CGD experts Amanda Glassman, Scott Morris, and Jeremy Konyndyk weigh in on some of the key points we heard (and live tweeted) during Secretary Tillerson’s testimony before the Senate Foreign Relations Committee and, later, when he answered questions from the Senate Appropriations Subcomm...
Blog Post
March 22, 2017
Cost-effectiveness analysis (CEA) can help countries attain and sustain universal health coverage (UHC), as long as it is context-specific and considered within deliberative processes at the country level. Institutionalising robust deliberative processes requires significant time and resources, howe...
Multimedia
March 22, 2017
The headline figure revealed in the "skinny budget" was 28.4 percent cuts to the State Department, USAID, and international programs. When other areas of spending directly relevant to development are considered, the actual level of cuts is over 30 percent. What do these cuts mean for ...
BRIEFS
June 04, 2012
Decisions about which type of patients receive what interventions, when, and at what cost often result from ad hoc, nontransparent processes driven more by inertia and interest groups than by science, ethics, and the public interest. Reallocating a portion of public and donor monies toward the most ...
REPORTS
June 04, 2012
Decisions about which type of patients receive what interventions, when, and at what cost often result from ad hoc, nontransparent processes driven more by inertia and interest groups than by science, ethics, and the public interest. Reallocating a portion of public and donor monies toward the most ...